Youtube
Twitter
Facebook
RepliCel Announces New Tendon Repair Technology Based on its Hair Follicle Cellular Expertise
VANCOUVER, BC – April 30, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CDNX:RP) is pleased to announce that it is initiating the clinical development of a new autologous cell therapy for the treatment of a variety of chronic tendon injuries including Achilles, patellar and elbow. This technology is based on ... Continue reading
RepliCel Receives Issue Notification from the United States Patent and Trademark Office Protecting Methods of Preparing Dermal Sheath Cup Cells for its Hair Regeneration Technology
VANCOUVER, BC – April 18, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) is pleased to announce that it has received issue notification from the United States Patent and Trademark Office with respect to RepliCel’s technology for preparing populations of dermal sheath cup cells for its hair regeneration procedure. These ... Continue reading
RepliCel Announces Closing of Private Placement
RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF and CNSX: RP) is pleased to announce the closing of a private placement financing (the “Financing”), pursuant to which it has issued 1,643,555 units at a price of CAD$0.31 per unit for gross proceeds of CAD$509,502. Each unit issued consisted of one common share of ... Continue reading
RepliCel to Present at the 11th Annual BioPartnering North America Conference
Vancouver Convention Centre, Vancouver, BC, February 24-26th, 2013 VANCOUVER, BC – February 19th 2013 – RepliCel Life Sciences Inc (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX: RP) today announced that the Company will present to a select group of biotech industry investors and experts at the 11th Annual BioPartnering North America Conference (“BPN”) in Vancouver, ... Continue reading
RepliCel Announces Re-Pricing of Warrants
VANCOUVER, BC – February 8, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) announces that it has received Exchange approval to amend the exercise price of the non-transferable common share purchase warrants (“Warrants”) expiring February 29, 2014, March 29, 2014, April 18, 2014 and April 20, 2014 from US$2.50 to ... Continue reading